Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Diffuse Large B-Cell Lymphoma remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 1,020 matched trial records and 1,948 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07702851 | Polatuzumab Vedotin-Piiq + Glofitamab | Phase 2; Not yet recruiting | Yonsei University | Geography not listed | Complete response rate at the end of treatment (At the end of treatment (EOT), up to approximately 36 weeks after the first…) | 2030-08-31 |
| NCT07691606 | ARC-02 + Rituximab | Phase 1; Recruiting | Taiho Oncology, Inc. | United States, Poland, Italy, France, Australia +1 more | Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) (Up to 5 years); Dose Escalation: Number of Participants with Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Up to 5 years) | 2029-01-01 |
| ChiCTR2600127766 | Intervention not normalized | Not Applicable; Recruiting | Henan Cancer Hospital | China | Objective response rate at the end of induction therapy. | 2026-09-01 |
| ChiCTR2600127644 | Luvometinib | Not Applicable; Not yet recruiting | Peking Union Medical College Hospital; Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences | China | Progression-free survival (PFS) | 2028-07-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma (Phase 1/2): the indexed record reports Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A = 0 Participants; Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A = 0 Participants; -.
- Acalabrutinib in Combination With Anti-CD19 Chimeric Antigen Receptor T-Cells (CART) in B-Cell Lymphoma (Phase 1/2): the indexed record reports -; Incidence of Adverse Events = 9 Participants; -.
- Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma (Phase 1): the indexed record reports ORR(At the RP2D) = 58.0 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Polatuzumab Vedotin-Piiq (Approved; CD79B x Tubulin), Glofitamab (Approved; CD20 x CD3), ARC-02 (Phase 1; CD79B), Rituximab (Approved; CD20), Luvometinib (Approved; MEK1 x MEK2). Company & Deal Intelligence records identify sponsor context for Yonsei University, Taiho Oncology, Inc., Henan Cancer Hospital, Peking Union Medical College Hospital, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Diffuse Large B-Cell Lymphoma has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
